Detalhe da pesquisa
1.
Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
Eur J Clin Pharmacol
; 75(11): 1565-1574, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392364
2.
Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
Eur J Clin Pharmacol
; 74(12): 1593-1604, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30105453
3.
Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects.
Pharm Res
; 32(5): 1764-78, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25425054
4.
Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics.
J Pharmacokinet Pharmacodyn
; 42(6): 639-57, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26231433
5.
Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma.
Anal Bioanal Chem
; 405(1): 215-23, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23064707
6.
Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.
Int J Clin Pharmacol Ther
; 51(10): 771-9, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24040847
7.
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.
Clin Ther
; 42(1): 175-195, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31926605
8.
Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.
AAPS J
; 18(1): 196-209, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26538125